Developer docs
API playgroundTry for free, no card

Search company profiles

Vital Tears

Full company profile

uuid000drfi

Namestring
Vital Tears
Legal namestring
Vital Tears LLC
Websiteurl
vitaltears.org
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Vital Tears is a U.S. specialty laboratory company that processes and distributes autologous serum eye drops made from a patient's own blood serum for the treatment of ocular surface disease. Founded in 2015 and headquartered in Kansas City, Missouri, the company serves patients with severe dry eye, neurotrophic keratitis, Sjögren's syndrome-related dry eye, and post-surgical ocular surface conditions by acting as the operational intermediary between prescribing eye care providers (ophthalmologists and optometrists) and a nationwide blood collection and delivery infrastructure. Eye care providers register through the company's online Provider Portal, prescribe serum tears according to patient-specific concentration and dosing specifications, and Vital Tears coordinates the entire downstream workflow including blood draw scheduling, processing, quality control, and direct-to-patient shipment of finished eye drops.

At the core of the offering is a proprietary, standardized quality-controlled medical laboratory process that converts patient blood serum into customized, preservative-free autologous eye drops. The operational footprint includes a single in-house medical laboratory at the Kansas City headquarters and a nationwide network of more than 400 contracted blood collection facilities, supplemented by a mobile phlebotomy service for at-home blood draws. The platform integrates an online Provider Portal (portal.vitaltears.org) for registration, prescription ordering, account management, and order tracking, supported by a dedicated Patient Services team that coordinates scheduling, payment, and delivery logistics. The company commits to a 48-hour turnaround from blood draw to delivery anywhere in the continental United States, with finished product shipped cold or frozen directly to patients' homes or offices.

Vital Tears operates a B2B2C revenue model in which each patient prescription flows through the company's laboratory and distribution infrastructure. Pricing is set per treatment plan based on physician-ordered concentration and dosing, with services primarily delivered on a self-pay basis; the company provides claim forms and reimbursement documentation to support patients seeking partial reimbursement from insurance payers. Customer acquisition is enterprise field-sales-driven, targeting eye care providers through dedicated sales representatives, clinical education resources (provider information packets, case studies), and exhibition presence at major U.S. ophthalmology and optometry conferences including AAO, ASCRS, American Academy of Optometry, and regional society meetings. The company is a privately held Missouri LLC, does not disclose revenue, pricing specifics, or external funding rounds, and operates without a publicly identified parent company or institutional investor.

Short descriptiontext

Vital Tears is a U.S. specialty laboratory company that prepares autologous serum eye drops from patients' own blood, coordinating prescriptions from eye care providers through a nationwide blood collection and 48-hour delivery network for ocular surface disease patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersKansas City, United States
HQ citystring
Kansas City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
autologous serum tears, ophthalmic compounding, ocular surface disease treatment, specialty eye drop processing, medical laboratory services
Industry1 code
PRIMARYHLAFAMAG
Transfusion Medicine & Immunohematology (Blood Bank)
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Ophthalmic Compounding Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Serum Tears Prescription Processing
TypeOne Time License
Description

Revenue generated from processing autologous serum eye drops prescribed by eye care providers. Cost is based on treatment plan ordered by the doctor. Generally self-pay service, though some insurance companies reimburse when patients submit claims.

vitaltears.org
2Insurance Reimbursement Support
TypeProfessional Services
Description

While Vital Tears is primarily a self-pay service, the company provides insurance claim forms and support documentation to help patients submit claims for potential reimbursement from their insurance providers.

vitaltears.org
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details1 tier
1Treatment plan based pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Cost determined by the concentration and dosage ordered by the physician. Payment plans available. Patient Services team provides cost information upon request.

vitaltears.org
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Vital Tears prepares autologous serum eye drops made from a patient's own blood serum in a medical laboratory using a proprietary quality-controlled processing system. Eye care providers (ophthalmologists and optometrists) prescribe customized serum tears that are produced to physician-specified concentration and dosage, then shipped to patients anywhere in the United States in as little as 48 hours after the blood draw. The company coordinates the entire workflow including provider ordering, blood collection logistics, laboratory processing, and direct patient delivery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Serum tears delivered in as little as 48 hours after blood draw, regardless of patient location in the United States
+2 more records
Product overview1 text field

Vital Tears offers a single core product: autologous serum eye drops made from a patient's own blood serum. The service is delivered through an integrated platform combining the Provider Portal (for order management and provider registration), a nationwide network of over 400 blood collection facilities plus mobile phlebotomy services, and Patient Services coordination for scheduling, payment, and delivery. Educational resources including the Provider Information Packet and Clinical Education Materials support provider adoption and clinical decision-making.

Product and service4 records
1Vital Tears Autologous Serum Eye Drops
CategoryOphthalmic Compounding Services
Description

Customized autologous eye drops made from a patient's own blood serum, prepared in Vital Tears' medical laboratory using a proprietary quality-controlled processing system, and delivered to patients anywhere in the United States in as little as 48 hours after blood draw. Preservative-free and produced at physician-specified concentration and dosage.

2Vital Tears Provider Portal
CategoryOrdering Platform
Description

Online portal that enables eye care providers to register, place orders for serum tears, manage doctor accounts, locate blood collection facilities, and track patient orders.

3Vital Tears Mobile Phlebotomy Service
4Vital Tears Blood Collection Facility Network
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Over 400 contracted blood collection facilities throughout the United States that perform blood draws for Vital Tears patients. These facilities are part of the essential supply chain enabling nationwide serum tear delivery within 48 hours of blood draw.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Mobile phlebotomy service partner enabling at-home blood draws for patients who prefer not to visit a collection facility or have limited access to contracted facilities.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1ImprimisRx (Harrow Health)
TypeDirect peer
Description

ImprimisRx is/was one of the largest US compounding pharmacies, historically producing and distributing autologous serum eye drops across the US as a direct competitor to Vital Tears using a similar ophthalmologist-prescribed, compounded-from-patient-blood model.

TypeDirect peer
Description

Parent of ImprimisRx; Harrow Health operated in the ophthalmic pharmaceutical compounding space and competed directly with Vital Tears in autologous serum tear preparation and distribution prior to its strategic shift toward branded ophthalmic drugs.

TypeBroad incumbent
Description

Major ophthalmic company with a broad eye-care portfolio including artificial tears (Soothe, TheraTears) and prescription ophthalmics; competes for the same dry-eye and ocular surface disease prescriber attention and OTC patient spend as Vital Tears.

TypeBroad incumbent
Description

Marketer of Restasis (cyclosporine ophthalmic) and other ocular surface disease treatments; competes for prescriber mindshare and patient spend in dry-eye disease where Vital Tears is positioned.

TypeBroad incumbent
Description

World's largest dedicated ophthalmic company with broad portfolio across dry eye, surgical, and vision care; competes for the same prescriber audience as Vital Tears and represents a logical strategic acquirer for direct-to-patient chronic-care infrastructure.

TypeEmerging player
Description

Clinical-stage ophthalmic company developing sustained-release drug delivery for ocular surface disease and adjacent indications; overlaps with Vital Tears' prescriber base and dry-eye / ocular surface disease therapeutic area.

TypeEmerging player
Description

Clinical-stage biotech developing novel treatments for ocular surface disease (dry eye); competes for the same prescriber recommendations and patient populations that Vital Tears addresses via autologous serum tears.

TypeEmerging player
Description

European ophthalmic company focused on ocular surface disease therapeutics; adjacent in target indication and competing for prescriber and patient attention in dry eye, though primarily operating in European markets.

9TheraTears
TypeOthers
Description

Brand of artificial tears (Bausch + Lomb) targeting dry-eye patients; provides the OTC self-pay alternative for patients who decline or cannot access autologous serum tears, establishing the price/value reference point against which Vital Tears must justify premium pricing.

TypeOthers
Description

Specialty and compounding pharmacy that prepares and dispenses autologous serum tears and other ophthalmic compounds; competes at the compounding-pharmacy end of the serum-tears market and offers an alternative distribution channel for prescribers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vital Tears

Ophthalmic Compounding Servicesvitaltears.org

Vital Tears is a U.S. specialty laboratory company that prepares autologous serum eye drops from patients' own blood, coordinating prescriptions from eye care providers through a nationwide blood collection and 48-hour delivery network for ocular surface disease patients.

What Vital Tears does

Vital Tears is a U.S. specialty laboratory company that processes and distributes autologous serum eye drops made from a patient's own blood serum for the treatment of ocular surface disease. Founded in 2015 and headquartered in Kansas City, Missouri, the company serves patients with severe dry eye, neurotrophic keratitis, Sjögren's syndrome-related dry eye, and post-surgical ocular surface conditions by acting as the operational intermediary between prescribing eye care providers (ophthalmologists and optometrists) and a nationwide blood collection and delivery infrastructure. Eye care providers register through the company's online Provider Portal, prescribe serum tears according to patient-specific concentration and dosing specifications, and Vital Tears coordinates the entire downstream workflow including blood draw scheduling, processing, quality control, and direct-to-patient shipment of finished eye drops.

At the core of the offering is a proprietary, standardized quality-controlled medical laboratory process that converts patient blood serum into customized, preservative-free autologous eye drops. The operational footprint includes a single in-house medical laboratory at the Kansas City headquarters and a nationwide network of more than 400 contracted blood collection facilities, supplemented by a mobile phlebotomy service for at-home blood draws. The platform integrates an online Provider Portal (portal.vitaltears.org) for registration, prescription ordering, account management, and order tracking, supported by a dedicated Patient Services team that coordinates scheduling, payment, and delivery logistics. The company commits to a 48-hour turnaround from blood draw to delivery anywhere in the continental United States, with finished product shipped cold or frozen directly to patients' homes or offices.

Vital Tears operates a B2B2C revenue model in which each patient prescription flows through the company's laboratory and distribution infrastructure. Pricing is set per treatment plan based on physician-ordered concentration and dosing, with services primarily delivered on a self-pay basis; the company provides claim forms and reimbursement documentation to support patients seeking partial reimbursement from insurance payers. Customer acquisition is enterprise field-sales-driven, targeting eye care providers through dedicated sales representatives, clinical education resources (provider information packets, case studies), and exhibition presence at major U.S. ophthalmology and optometry conferences including AAO, ASCRS, American Academy of Optometry, and regional society meetings. The company is a privately held Missouri LLC, does not disclose revenue, pricing specifics, or external funding rounds, and operates without a publicly identified parent company or institutional investor.

Vital Tears firmographics

Firmographics
Name
Vital Tears
Legal name
Vital Tears LLC
Website
https://vitaltears.org
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Vital Tears is a U.S. specialty laboratory company that prepares autologous serum eye drops from patients' own blood, coordinating prescriptions from eye care providers through a nationwide blood collection and 48-hour delivery network for ocular surface disease patients.
Ownership category
akta.pro rank

Vital Tears industry classification

Industry
Product category
Ophthalmic Compounding Services
NAICS
Medical Equipment and Supplies Manufacturing (3391)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAFAMAG
Transfusion Medicine & Immunohematology (Blood Bank)

Keywords

  • Autologous serum tears
  • Ophthalmic compounding
  • Ocular surface disease treatment
  • Specialty eye drop processing
  • Medical laboratory services

Where Vital Tears is headquartered

Location

Headquarters

HQ city
Kansas City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Vital Tears business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Serum Tears Prescription Processing: Revenue generated from processing autologous serum eye drops prescribed by eye care providers. Cost is based on treatment plan ordered by the doctor. Generally self-pay service, though some insurance companies reimburse when patients submit claims.
  2. Insurance Reimbursement Support: While Vital Tears is primarily a self-pay service, the company provides insurance claim forms and support documentation to help patients submit claims for potential reimbursement from their insurance providers.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goTreatment plan based pricing

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Vital Tears product offering

Product offering

Core offering

Vital Tears prepares autologous serum eye drops made from a patient's own blood serum in a medical laboratory using a proprietary quality-controlled processing system. Eye care providers (ophthalmologists and optometrists) prescribe customized serum tears that are produced to physician-specified concentration and dosage, then shipped to patients anywhere in the United States in as little as 48 hours after the blood draw. The company coordinates the entire workflow including provider ordering, blood collection logistics, laboratory processing, and direct patient delivery.

Product overview

Vital Tears offers a single core product: autologous serum eye drops made from a patient's own blood serum. The service is delivered through an integrated platform combining the Provider Portal (for order management and provider registration), a nationwide network of over 400 blood collection facilities plus mobile phlebotomy services, and Patient Services coordination for scheduling, payment, and delivery. Educational resources including the Provider Information Packet and Clinical Education Materials support provider adoption and clinical decision-making.

Differentiator

Problem solved

Functional benefit

Products and services

  • Vital Tears Autologous Serum Eye Drops Customized autologous eye drops made from a patient's own blood serum, prepared in Vital Tears' medical laboratory using a proprietary quality-controlled processing system, and delivered to patients anywhere in the United States in as little as 48 hours after blood draw. Preservative-free and produced at physician-specified concentration and dosage.
  • Vital Tears Provider Portal Online portal that enables eye care providers to register, place orders for serum tears, manage doctor accounts, locate blood collection facilities, and track patient orders.
  • Vital Tears Mobile Phlebotomy Service
  • Vital Tears Blood Collection Facility Network

Quantifiable outcome

  • Serum tears delivered in as little as 48 hours after blood draw, regardless of patient location in the United States
  • +2 more outcomes

Companies that use Vital Tears

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Vital Tears technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Vital Tears partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Blood Collection Facilities NetworkcoreChannel Partner/ Reseller/ DistributorOver 400 contracted blood collection facilities throughout the United States that perform blood draws for Vital Tears patients. These facilities are part of the essential supply chain enabling nationwide serum tear delivery within 48 hours of blood draw.
  • Mobile Phlebotomy ServicecoreChannel Partner/ Reseller/ DistributorMobile phlebotomy service partner enabling at-home blood draws for patients who prefer not to visit a collection facility or have limited access to contracted facilities.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Vital Tears competitors and assessment

Company assessment

Direct peers

  • ImprimisRx (Harrow Health): ImprimisRx is/was one of the largest US compounding pharmacies, historically producing and distributing autologous serum eye drops across the US as a direct competitor to Vital Tears using a similar ophthalmologist-prescribed, compounded-from-patient-blood model.
  • Harrow Health: Parent of ImprimisRx; Harrow Health operated in the ophthalmic pharmaceutical compounding space and competed directly with Vital Tears in autologous serum tear preparation and distribution prior to its strategic shift toward branded ophthalmic drugs.

Broad incumbents

  • Bausch + Lomb: Major ophthalmic company with a broad eye-care portfolio including artificial tears (Soothe, TheraTears) and prescription ophthalmics; competes for the same dry-eye and ocular surface disease prescriber attention and OTC patient spend as Vital Tears.
  • Allergan (AbbVie): Marketer of Restasis (cyclosporine ophthalmic) and other ocular surface disease treatments; competes for prescriber mindshare and patient spend in dry-eye disease where Vital Tears is positioned.
  • Alcon: World's largest dedicated ophthalmic company with broad portfolio across dry eye, surgical, and vision care; competes for the same prescriber audience as Vital Tears and represents a logical strategic acquirer for direct-to-patient chronic-care infrastructure.

Emerging players

  • Ocular Therapeutix: Clinical-stage ophthalmic company developing sustained-release drug delivery for ocular surface disease and adjacent indications; overlaps with Vital Tears' prescriber base and dry-eye / ocular surface disease therapeutic area.
  • Aldeyra Therapeutics: Clinical-stage biotech developing novel treatments for ocular surface disease (dry eye); competes for the same prescriber recommendations and patient populations that Vital Tears addresses via autologous serum tears.
  • Nicox: European ophthalmic company focused on ocular surface disease therapeutics; adjacent in target indication and competing for prescriber and patient attention in dry eye, though primarily operating in European markets.

Others

  • TheraTears: Brand of artificial tears (Bausch + Lomb) targeting dry-eye patients; provides the OTC self-pay alternative for patients who decline or cannot access autologous serum tears, establishing the price/value reference point against which Vital Tears must justify premium pricing.
  • Avella Specialty Pharmacy: Specialty and compounding pharmacy that prepares and dispenses autologous serum tears and other ophthalmic compounds; competes at the compounding-pharmacy end of the serum-tears market and offers an alternative distribution channel for prescribers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Vital Tears social profiles

Digital presence

Vital Tears financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vital Tears leadership team

Management profile

Number of profiles

Profiles9 records

Vital Tears funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vital Tears M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vital Tears

What does Vital Tears do?

Vital Tears prepares autologous serum eye drops made from a patient's own blood serum in a medical laboratory using a proprietary quality-controlled processing system. Eye care providers (ophthalmologists and optometrists) prescribe customized serum tears that are produced to physician-specified concentration and dosage, then shipped to patients anywhere in the United States in as little as 48 hours after the blood draw. The company coordinates the entire workflow including provider ordering, blood collection logistics, laboratory processing, and direct patient delivery.

Is Vital Tears a public or private company?

Vital Tears is a private company. It is classified as management employee owned and is currently operating.

When was Vital Tears founded?

Vital Tears was founded in 2015. It employs 11 to 50 people.

Where is Vital Tears based?

Vital Tears is headquartered in Kansas City, United States, in the North America region.

How does Vital Tears make money?

Two revenue lines are on record. Serum Tears Prescription Processing is the primary driver. The others are insurance Reimbursement Support.

Who are Vital Tears's main competitors?

Direct peers on record are ImprimisRx (Harrow Health) and Harrow Health. Broad incumbents are Bausch + Lomb, Allergan (AbbVie) and Alcon. Emerging players are Ocular Therapeutix, Aldeyra Therapeutics and Nicox. Others are TheraTears and Avella Specialty Pharmacy.

Does Vital Tears have an API?

No public API is recorded for Vital Tears.

What industry is Vital Tears in?

Vital Tears's product category is Ophthalmic Compounding Services. Its primary akta.pro industry code is HLAFAMAG, Transfusion Medicine & Immunohematology (Blood Bank). Its NAICS code is 3391 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales